

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 December 2024 (05.12.2024)



(10) International Publication Number
WO 2024/246496 A1

(51) International Patent Classification:

C07D 209/12 (2006.01) A61P 21/02 (2006.01)
C07D 217/06 (2006.01) A61P 25/16 (2006.01)
C07D 403/06 (2006.01) A61P 25/28 (2006.01)
C07D 403/12 (2006.01) A61P 35/00 (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:

PCT/GB2024/051337

(22) International Filing Date:

23 May 2024 (23.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2307924.7 26 May 2023 (26.05.2023) GB

(71) Applicant: **NEOPHORE LIMITED** [GB/GB]; 3rd Floor,
1 Ashley Road, Altrincham, Altrincham Cheshire WA14
2DT (GB).

(72) Inventors: **BLAGG, Julian**; c/o NeoPhore Limited, 3rd
Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT
(GB). **DRYSDALE, Martin**; c/o NeoPhore Limited, 3rd
Floor, 1 Ashley Road, Altrincham Cheshire WA14 2DT
(GB). **WINSHIP, Paul Colin Michael**; c/o Charles River
Discovery Research Services UK Limited, Robinson Building,
Chesterford Research Park, Little Chesterford, Saffron
Walden Essex CB10 1XL (GB). **RANKIN, Stuart Shane**;
c/o Charles River Discovery Research Services UK Limited,
Robinson Building, Chesterford Research Park, Little
Chesterford, Saffron Walden Essex CB10 1XL (GB).
RAE, Alastair; c/o Charles River Discovery Research Services
UK Limited, Robinson Building, Chesterford Research
Park, Little Chesterford, Saffron Walden Essex CB10
1XL (GB). **BESTWICK, Jacob Scottie**; c/o Charles River
Discovery Research Services UK Limited, Robinson Building,
Chesterford Research Park, Little Chesterford, Saffron
Walden Essex CB10 1XL (GB). **TINSON, Ryan Alan
James**; c/o Charles River Discovery Research Services UK
Limited, Robinson Building, Chesterford Research Park,

Little Chesterford, Saffron Walden Essex CB10 1XL (GB).
MULLA, Mushtaq; c/o Charles River Discovery Research
Services UK Limited, Robinson Building, Chesterford Research
Park, Little Chesterford, Saffron Walden Essex CB10
1XL (GB). **MIDDLETON, Anthony James**; Charles River
Discovery Research Services UK Limited, Robinson Building,
Chesterford Research Park, Little Chesterford, Saffron
Walden Essex CB10 1XL (GB).

(74) Agent: **HGF LIMITED**; 1 City Walk, Leeds West Yorkshire
LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND
DEGENERATIVE ILLNESSES



(I)

(57) Abstract: The present invention relates to compounds of Formula (I) that target PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: (I) wherein R², R³, R⁴, R⁵, X, Y¹, Y², A¹, A², A³ and A⁴, and any groups associated therewith, are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PMS2 activity is implicated.

WO 2024/246496 A1